Cosmos Health issues 2026-2029 guidance targeting $200m revenue by 2029
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- UBS sees generational semiconductor boom, highlights stock winners
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash G
May 26, 2026 9:34 AM EDTRevenue increasing 207% at a 32% CAGR: From $65.3 million in 2025 to $200.6 million by 2029, driven by strong growth across all core segmentsGross profit growing 801% to $71.2M: Margins expanding from 12.1% to 35.5% driven by a structural shift toward high-margin proprietary segmentsNet income improving by $50.1M: Transition to profitability in 2027; net income of $31.0 million by 2029Self-funding growth model: Operating cash flow turning positive in 2027 at $11.9 million, more than doubling to $24.0 million by 2029Balance sheet transformation: Cash up 18-fold to $62.9 million; all convertible notes repaid; cash anticipated to exceed total debt... More
